Articles: 25.10 19 May 2014

Diagnosis and recommended treatment of helminth infections

A number of worm infections are seen in the UK, often in migrants from tropical countries, and it is essential to take a travel history. Our Drug review discusses the features of the most common infections and details currently recommended treatments.
Diagnosis and recommended treatment of …

More details...

Fluorouracil is the most effective therapy for actinic keratosis

This network meta-analysis found that fluorouracil (Efudix) is the most effective treatment for actinic keratosis, based on the outcome of participant complete clearance.
Fluorouracil is the most effective therapy for actinic keratosis

More details...

Implementing value-based assessment of medicines

Steve Chaplin examines NICE’s proposals to introduce two weighting systems into its technology appraisal process in order to better reflect the value of new treatments.
Implementing value based assessment of medicines

More details...

Improving anticoagulant prescribing for AF

Anticoagulants are effective at preventing strokes in AF, but there is concern that GPs are not adequately prescribing them. Here, the authors discuss the barriers to prescribing anticoagulants and how to increase their use.
Improving anticoagulant prescribing for AF

More details...

Professor Teeling Smith and The Politics of Prescribing

In our series on the history of prescribing policy, Dr Darrin Baines traces how successive governments have attempted to curb drug costs. Here, he describes Professor Teeling Smith’s warning of the dangers of a ‘cheap drugs’ policy in 1985.
Professor Teeling Smith and The Politics of …

More details...

Relvar Ellipta: new once-daily steroid/LABA inhaler

Relvar Ellipta is a new inhaled steroid/long-acting beta-agonist combination taken once daily. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse events, and Professor Neil Thomson discusses its place in therapy.
Relvar Ellipta new once daily steroid LABA inhaler

More details...

Updated NICE guidance on OA: emphasis remains the same

Osteoarthritis (OA) is a common, disabling and costly condition managed mainly in primary care. A rise in prevalence is partly explained by increasing obesity and longevity. NICE CG177 (February 2014) updates the 2008 guidance on this topic. In the light of recent evidence a number …

More details...

Latest reviews from Cochrane

In this section we present an abstract of a review relevant to prescribing in general practice from the latest issue of The Cochrane Database of Systematic Reviews. To view the article in full or for further information, visit www.thecochranelibrary.com
Vitamin D and vitamin D analogues for …

More details...

Web design and marketing agency Leamington Spa